We observed that N-(4-hydroxyphenyl)retinamide (4HPR), a chemopreventive and chemotherapeutic agent, effectively induced apoptosis in hepatoma cells. Interestingly, Fas-negative (Hep 3B and PLC/PRF/5) hepatoma cells were shown to be more susceptible to apoptosis induced by 4HPR than were Fas-positive (Hep G2 and SK-HEP-1) hepatoma cells. Thus, we explored the mechanisms underlying 4HPR-induced apoptosis in Fas-defective hepatoma cells. Hep 3B cells stably expressing the dominant-negative Fas-associated death domain (dnFADD) showed no alteration in 4HPR drug susceptibility, but when stably expressing E1B19K, Crm A, or dominant-negative FLICE (dnFLICE), Hep 3B cells were resistant, suggesting that 4HPR-induced apoptosis was mediated by caspase-8 activation. Furthermore, apoptosis could be completely blocked by Z
Among retinoids, N-(4-hydroxyphenyl)retinamide (4HPR)
is a synthetic derivative that exhibits low toxicity and longterm tolerability in humans and in other animals, 1,2 and which seems very promising in terms of its effectiveness relative to toxicity. 4HPR also induces apoptosis of human neuroblastoma cells, 3, 4 human ovarian carcinoma cells, 5 and human malignant hematopoietic cells, 6 including cells carrying mutations of the retinoic acid receptor that are unresponsive to all-trans-retinoic acid. Recently, it was shown that cell killing by 4HPR is antagonized by deregulated Bcl-2 expression as well as by certain antioxidants. 7 4HPR stimulates the generation of intracellular free radicals, which strongly suggests that the mechanism of its action is linked to apoptosis-inducing oxidative stress. 8 4HPR-induced apoptosis is suppressed by a nuclear retinoic acid receptor-specific antagonist, suggesting the involvement of those receptors in mediating apoptosis. Furthermore, some apoptosis-related genes (p21, c-myc, and c-jun) also contribute to the induction of apoptosis by 4HPR. 9 However, the specific mechanism of 4HPR-induced apoptosis is still unclear.
Human hepatocellular carcinoma (HCC), one of the most frequently occurring tumors worldwide, is resistant to chemotherapy and radiation. Fas is important in the regulation of apoptosis in hepatocytes, and it plays a significant role in the pathogenesis of hepatic disease, including liver injury, hepatitis, cirrhosis, and HCC. 10, 11 Fas expression is restricted to certain areas or is completely lost in HCC. 12 Even human hepatoma cells express detectable levels of Fas on their surfaces, and, unlike hepatocytes, they are resistant to apoptosis after treatment with anti-Fas antibody. 13 Thus, the failure of Fas-mediated apoptosis caused by a loss of Fas expression or by a defect in the Fas-activated signaling pathway may be involved in hepatocarcinogenesis. Moreover, Fas may contribute to the chemoresistance of HCC, because the Fas/Fas ligand (Fas-L) system plays a key role in chemotherapeutic drug-induced apoptosis in tumors. [14] [15] [16] However, 4HPR readily induces apoptosis in Fas-defective hepatoma cells. Thus, to delineate the molecular mechanisms of 4HPR-induced cell death and to understand the rationale of 4HPR retinoid antitumor effects, we have now characterized the roles of the adapter protein, Fas-associated death domain (FADD), and of caspases, which are downstream of Fas, in the promotion of the apoptosis signal. Furthermore, we have investigated the link of this apoptotic signal to mitochondrial oxidative stress.
In this study, we observed that 4HPR-triggered apoptosis occurs in Fas-defective cells and that 4HPR treatment initiates early caspase-8 activation, followed by late cytochrome c release. The direct caspase-8 inhibitors, including E1B19K, poxvirus serpin CrmA, dominant-negative FLICE (dn-FLICE), Z-VAD-FMK (a general caspase inhibitor), and IETD-CHO (a caspase-8 inhibitor), effectively inhibited 4HPR-induced apoptosis. The results suggest that early caspase-8 activation is the primary up-stream regulatory point of this cell-execution cascade. Mitochondrial cytochrome c release and caspase-9 activation are also involved in the 4HPR-induced apoptosis, but seem to play a minor role.
MATERIALS AND METHODS
Chemical Reagents and Antibodies. 4HPR, kindly supplied by Johnson Pharmaceutical Research Institute (Spring House, PA), was dissolved in absolute ethanol at a concentration of 10 Ϫ2 mol/L and was stored in aliquots at Ϫ20°C for a maximum of 1 week. Antioxidants used included N-acetyl-L-cysteine (NAC), pyrrolidine dithiocarbamate (PDTC), nordihydroguaiaretic acid (NDGA), and the serine threonine protease inhibitor, N-tosyl-L-phenylalanine chloromethylketone (TPCK), and were obtained from Sigma (St. Louis, MO). Antioxidant solutions were made just before use in fresh medium, and the pH was adjusted to 7.4. TPCK was dissolved in dimethylsulfoxide (DMSO) at 50 mmol/L and was stored in small aliquots at Ϫ20°C. The mitochondrial permeability transition inhibitor, cyclosporin A (CsA), and the calpain inhibitor I, N-acetyl-leucyl-leucylnorleucinal (ALLN), were purchased from Calbiochem (San Diego, CA). The caspase inhibitors, Z-VAD-FMK, Ac-DEVD-CMK (a caspase-3 inhibitor), Z-WEHD-FMK (a caspase-5 inhibitor), IETD-CHO, and Z-LEHD-FMK (a caspase-9 inhibitor) were from Calbiochem and were dissolved in DMSO at 50 mmol/L. In all experiments, the final concentration of DMSO did not exceed 0.1% (vol/vol), a concentration that is nontoxic to the cells. Antibodies to FADD, poly(ADP-ribose)polymerase (PARP), caspase-3, caspase-8, Bid, and Bcl-2 were from PharMingen (San Diego, CA), while antibodies to Fas-L, Bax, and Bcl-xL were from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell Culture, Transfection, and Apoptosis Assay. Four hepatoma cell lines (Hep 3B, PLC/PRF/5, Hep G2, and SK-HEP-1) were obtained from the American Tissue Culture Collection (ATCC, Rockville, MD). Cells were cultured and treated with 10 mol/L or various concentrations of 4HPR in Dulbecco's minimum essential medium supplemented with 10% fetal bovine serum in air containing 5% CO 2 . The percentage of apoptotic cells was evaluated by Hoechst 33258 staining (1 mol/L in phosphate-buffered saline [PBS] ; Sigma) as previously described. 17 At least 200 cells were counted for each time point, and all counting was performed in a blinded fashion. To assess the influence of FADD and caspase on drug-induced apoptosis, cells (1 ϫ 10 5 ) were transfected with 1 g of vector control or an expression plasmid of dnFADD (pcDNA3-dnFADD), 18 E1B 19K (pCMV-E1B 19K), 19 CrmA (pCI-CrmA), 20 or dnFLICE (pcDNA3-dnFLICE) 21 by lipofectin transfection, according to the manufacturer's instructions (Gibco, Grand Island, NY). Stable transfectants were obtained 2 to 3 weeks after selection with 600 g/mL G418. The cells were expanded and verified for the expression of each mRNA. Stable transfectants were incubated with 10 mol/L 4HPR for 72 hours in 60-mm dishes. The percent viability was determined by Trypan blue dye exclusion.
Terminal Deoxynucleotidyl Transferase Assay. In situ detection of fragmented DNA was performed on cytospin preparations. 22 Treated or untreated cells, at approximately 1 ϫ 10 5 cells per milliliter, were cytocentrifuged on glass slides, air-dried, fixed in 2% paraformaldehyde and then in acetone, washed in PBS, and then incubated with terminal deoxynucleotidyl transferase (Oncor, S7100-kit) in TdT buffer. Digoxigenin incorporation was detected with antidigoxigenin-peroxidase conjugation, and was then visualized with diaminobenzidine-H 2 O 2 (Vector Laboratories, Kit SK-400).
Flow Cytometry. Apoptotic/hypodiploid cells were measured using a modification of the technique described previously. 23 Cells were treated with 10 mol/L 4HPR for 72 hours and were collected for flow cytometry (FCM) using a FACScan (Becton-Dickinson, San Jose, CA) with an argon laser set to excite at 488 nm. Monolayer cells and detached cells harvested with trypsin were fixed in 70% ethanol and were stored at 4°C. Propidium iodide (40 g/100 L PBS) was added to 1 ϫ 10 6 cells suspended in 800 L PBS together with 100 L RNase A (1 g/mL), and the suspension was incubated at 37°C for 30 minutes before FCM analysis of 2 ϫ 10 4 cells. Red fluorescence resulting from propidium-bound DNA was measured using a 630-nm-long bandpass filter. Data were analyzed as single-parameter frequency histograms in an SFIT model. The sub-G 1 fraction was estimated by gating hypodiploid cells in the DNA histogram using a C-30 program.
Total RNA Preparation and Reverse-Transcriptase Polymerase Chain Reaction. Total RNA was extracted from treated or untreated cells using a phenol and guanidine thiocyanate solution (Tri Reagent; Molecular Research Center Inc., Cincinnati, OH) following the manufacturer's instructions. mRNA was reverse-transcribed with oligo d(T)15 primers (Boehringer Mannheim, Mannheim, Germany) to prepare singlestranded cDNA, followed by polymerase chain reaction (PCR) amplification of Fas mRNA. Amplification was performed for 30 cycles for ␤Ϫactin as an internal control and for Fas in a thermal cycler (Perkin Elmer, Norwalk, CT). Each cycle consisted of 1 minute of denaturation at 94°C, 1 minute of annealing at 57°C, and 1 minute of extension at 72°C. The sequences of primers used were as follows: Fas (forward: 5Ј-CGGAGGATTGCTAACAAC-3Ј; reverse: 5Ј-TTG-GTATTCTGGGTCCG-3Ј), 24 and ␤-actin (forward: 5Ј-CGTTCTG-GCGGCACCACCAT-3Ј; reverse: 5Ј-GCAACTAAGTCATAGTC-CGC-3Ј). The PCR products were analyzed by 1.2% agarose gel electrophoresis.
Northern Blot Analysis. Cells were cultured in Dulbecco's minimum essential medium with 10% fetal bovine serum until 60% confluency and were then treated with 10 mol/L 4HPR for 48 hours. Total RNA was extracted from treated or from untreated cells as described above, then fractionated by electrophoresis on 1.0% agarose gels containing formaldehyde, and transferred to membranes. Blots were hybridized overnight with 2 ϫ 10 6 cpm per milliliter of cDNA probe labeled with [P 32 ]dCTP (NEN, Boston, MA) by random-priming, washed, then exposed to x-ray film at Ϫ70°C, as described previously. 25 Unbound probes were removed by submerging the membranes in hot water for a few minutes, and membranes were then rehybridized with the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe to normalize for the amount of RNA loaded. The cDNA probe for Bid was a kind gift from Dr. Xiadong Wang.
Measurement of Caspase Protease Activity. To measure the enzymatic activity of caspase proteases, Hep 3B cells treated with 10 mol/L 4HPR were lysed in lysis buffer (1% Triton X-100, 0.32 mol/L sucrose, 5 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride (PMSF), 1 g/mL aprotinin, 1 mol/L leupeptin, 2 mmol/L dithiothreitol, and 10 mmol/L Tris/HCl [pH 8.0]) on ice for 30 minutes, and were then cleared at 15,000g for 15 minutes for the indicated time intervals. The activities of caspase-1, -3, -6, -8, or -9 -like proteases were measured by proteolytic cleavage of substrates including 100 mol/L of Ac-WEHD-AMC (caspase-1 substrate), Ac-DEVD-AMC (caspase-3 substrate), AcVEID-AMC (caspase-6 substrate), Ac-IETD-AMC (caspase-8 substrate), or Ac-LEHD-AMC (caspase-9 substrate), respectively. These fluorogenic substrates (and AMC as a control) were solubilized in an assay buffer containing 100 mmol/L HEPES (pH 7.5), 10% sucrose, 0.1% 3-[(3-chloroamidopropyl)dimethylammonio]-1-propane-sulfonate, 1 mol/L PMSF, 1 g/mL aprotinin, 1 mol/L leupeptin, and 2 mmol/L dithiothreitol. After incubation at 37°C for 30 minutes in the dark, fluorescence from the lysates was measured with a fluorometer (Molecular Devices, Palo Alto, CA) at dual wavelengths (380-nm excitation and 460-nm emission).
Cell Lysis and Immunoblotting. Cells were lysed in a buffer containing 50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 1% Triton X-100, 5 mmol/L EDTA, 5 mmol/L ethylene glycol-bis(␤-aminoethyl ether) N,N,NЈ,NЈ-tetraacetic acid, 10 mmol/L NaF, 1 mmol/L Na 3 VO 4 , 1 mmol/L PMSF, 2 g/mL leupeptin, 1 mmol/L pepstatin, and 1 g/mL aprotinin. Twenty-five or 50 g of cell lysate was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and was transferred to Hybond membranes (Amersham Pharmacia Biotech, Uppsala, Sweden). The membranes were blocked with 5% skim milk and were then incubated with the designated primary antibodies, and signals were detected using an ECL Western blotting kit (Amersham Pharmacia Biotech).
Quantification. Autoradiographs of Western ligand blot analyses and Northern hybridizations were scanned using a Personal Densitometer SI (Molecular Dynamics, Sunnyvale, CA), and densitometric data were analyzed using the accompanying software on a Power Mac 6100 (Apple). The level of mRNA for GAPDH was determined in the same manner. Expression levels of each gene relative to the untreated control were calculated by normalizing against the level of GAPDH mRNA and then calculating the ratio of mRNAs from treated cells for indicated time intervals with untreated cells.
RESULTS

Quantitation of 4HPR-Induced Apoptosis.
Cells treated with 10 mol/L 4HPR were stained with the DNA-binding dye, Hoechst 33258, which revealed condensed chromatin and fragmented nuclear morphologies in Hep 3B and PLC/PRF/5 (Fas-negative) cells, while chromatin remained homogeneous and nuclei remained round in Hep G2 and SK-HEP-1 (Faspositive) cells. We then measured the apoptosis of cells treated with 4HPR at the indicated time intervals. This timecourse analysis demonstrated that within 72 hours, 38% Ϯ 3.6% (mean Ϯ SEM) of Hep 3B cells and 35% Ϯ 3.0% of PLC/PRF/5 cells were apoptotic, whereas only 10% of Hep G2 cells or SK-HEP-1 cells were apoptotic (Fig. 1A) . Condensed, fragmented nuclei were stained intensely by the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) method, 26 which detects the presence of DNA breaks characteristic of apoptosis. Numerous TUNEL-positive cells were detected in 4HPR-treated Hep 3B cells and PLC/PRF/5 cells (Fig. 1B) . To obtain a more objective and accurate quantification of apoptotic cell death, FCM analysis was performed between 4HPR-treated and untreated cells (Fig. 1C) . The percent of cells in the sub-G 1 fraction that were stained with propidium iodide following treatment with 10 mol/L 4HPR for 72 hours were 38.2% Ϯ 4.0% and 40.2% Ϯ 5.0% in Hep 3B cells and PLC/PRF/5 cells, respectively. In contrast, 4HPR did not increase the percent of cells in the sub-G 1 fraction of Hep G2 cells or SK-HEP-1 cells (10.8% Ϯ 1.2% and 6.4% Ϯ 0.9%, respectively), as compared with untreated cells, implying that both cell lines were resistant to 4HPR. These results were similar to those obtained for staining with the DNA-binding dye, Hoechst 33258. Hoeschst 33258 staining revealed that Hep G2 and SK-HEP-1 cells eventually became similarly apoptotic at higher concentrations of 4HPR (20 mol/L and 15 mol/L, respectively) as the Hep 3B and PLC/PRF/5 cells treated with 10 mol/L 4-HPR (Fig.1D) .
Caspase Activation by 4HPR. Constitutive RNA expression of Fas was detected by semiquantitative reverse transcriptase(RT)-PCR in Hep G2 and SK-HEP-1 cells, but not in Hep 3B or PLC/PRF/5 cells, which is consistent with previous reports. 15, 27 Treatment with 4HPR for 48 hours slightly decreased the expression level of Fas in Hep G2 or SK-HEP-1 cells. Expression of Fas-L and FADD proteins was intact in all 4 hepatoma cell lines as determined by immunoblot analysis, and their levels were not changed by 4HPR treatment (Fig.  2A) . To assess the effect of dnFADD expression on 4HPR-induced apoptosis, FCM analysis was performed between the stable transfectants and vector control cells following treatment with 10 mol/L 4HPR for 72 hours. Apoptotic fractions were then calculated and compared with control cells transfected with an empty vector. Apoptotic cells were clearly demonstrated in 4HPR-treated cells, but no significant difference in the apoptotic fraction was detected in Hep 3B cells compared with control cells (Fig. 2B) . The percent of cells in the sub-G 1 fraction that were stained with propidium iodide were 42.3% Ϯ 5.2% and 38.3% Ϯ 4.0% in dnFADD transfectants and vector control cells, respectively. E1B 19K, the adenovirus Bcl-2 homologue, inhibits Fas-mediated cell death downstream of FADD recruitment of caspase-8 but upstream of caspase-8 activation. 19 Hep 3B cells stably transfected with pCMV-E1B 19K showed a resistance to 4HPR compared with control cells (15.2% Ϯ 1.9% vs. 45.7% Ϯ 5.2%; P Ͻ 0.01). Crm A, a cowpox viral serpin that inhibits caspases-1, -4, and -8, but not caspases-3, -6, -7, or -10, 20,28 significantly protected Hep 3B cells from drug-induced apoptosis (10.4% Ϯ 2.0% vs. 36.6% Ϯ 2.5%; P Ͻ .01). dnFLICE also significantly inhibited 4HPR-induced apoptosis (15.6% Ϯ 1.4% vs. 36.3% Ϯ 2.9%; P Ͻ .01). The sum of these results suggests that 4HPR-induced apoptosis is independent of FADD function and is mediated by downstream FADD activation or upstream caspase-8 activation in Fas-defective hepatoma cells. These results were consistent with the quantification by staining with the DNA-binding dye, Hoechst 33258.
Modulation of 4HPR-Induced Apoptosis. Hep 3B cells were treated with 10 mol/L 4HPR for 3 days in the presence or absence of noncytotoxic doses of various inhibitors, including 2 mmol/L NAC, 0.25 mol/L CsA, 1 mol/L TPCK, 1 mol/L ALLN, or 50 mol/L Z-VAD-FMK. Only Z-VAD-FMK almost completely inhibited 4HPR-induced cell death, compared with treatment with 4HPR alone (10% Ϯ 0.9% vs. 38% Ϯ 1.2%), while NAC or ALLN partially inhibited it (24% Ϯ 1.6% or 29% Ϯ 1.4%, respectively). PDTC and NDGA also partially decreased cell death (data not shown). In contrast, CsA actually enhanced 4HPR-induced cell death (49% Ϯ 1.7%; P Ͻ .05), and TPCK did not alter cell viability (Fig. 3A) . To characterize the apoptotic roles of various caspases, cells were preincubated for 30 minutes in specific caspase inhibitors, including 50 mol/L Ac-DEVD-CMK, 50 mol/L Z-WEHD-FMK, 50 mol/L IETD-CHO, or 25 mol/L Z-LEHD-FMK, before 4HPR treatment. The caspase-8 inhibitor almost completely blocked 4HPR-induced apoptosis, but the caspase-3 inhibitor did not (19% Ϯ 2%; P Ͻ .01), while the caspase-9 inhibitor partially decreased cell death (29% Ϯ 3%; P Ͻ .05). In contrast, the caspase-5 inhibitor did not alter susceptibility to the drug-induced apoptosis (Fig. 3B) . Thus, activation of caspases-8 and -3 seem to play a major role in cell-death execution.
Caspase Activities. During 4HPR-induced apoptosis in Hep 3B cells, caspase-8 and caspase-3 activation could be detected within 12 hours of treatment, and caspase-8 activation was sustained thereafter to 72 hours. Caspase-3 activation peaked at 30 hours. In contrast, caspase-9 activation was increased to 2.5-fold of the unstimulated level at 72 hours (Fig. 4A) . The pattern of a minor activation of caspase-9 implied that the initiation of apoptosis by caspase-8 activation was linked to some mitochondrial stress. Immunoblot analysis showed that caspase-8, and PARP activation, started early within 24 hours after 4HPR treatment (Fig. 4B) . Cytochrome c release was overt, but caspase-9 activation was just barely detected after 72 hours of treatment, implying that attenuated caspase-9 activation was not sufficient to be detected in immunoblot analysis, and that there was an interruption between cytochrome c release and caspase-9 activation.
Involvement of Bid, Bax, or Bcl-xL in 4HPR-Induced Apoptosis.
Bid is known as a mediator of mitochondrial damage induced by caspase-8 activation. Thus, we determined whether Bid was involved in this drug-induced apoptosis. The expression of Bid mRNA was not altered in Hep 3B or PLC/PRF5 cells treated with 4HPR for 48 hours. In contrast, 4HPR prominently induced Bid mRNA expression in Hep G2 and SK-HEP-1 cells (Fig. 5A) . To clarify this regulation, the Fas-defective Hep 3B cells treated with 4HPR were analyzed at the indicated time intervals by Western blot analyses (Fig. 5B) . Hep 3B cells did not show any time-dependent alteration of Bid protein levels, whereas SK-HEP-1 cells showed an increase in the expression of Bid protein 72 hours after treatment with 4HPR, which was consistent with the Northern analysis. Bid is a BH3 domain-containing protein known to interact with both Bcl-2 and Bax. 29 The cytochrome c-releasing activity of Bid is antagonized by Bcl-2 or by Bcl-xL. 30 Therefore, we deter- mined Bcl-2, Bax, and Bcl-xL expression in hepatoma cells treated with 4HPR. Interestingly, Hep 3B, PLC/PRF/5, and Hep G2 cells were negative for Bcl-2 expression (Fig. 6A) , which is in accordance with a previous report. 31 4HPR did not change the expression of Bax in Hep 3B cells (Fig. 6B) . However, 4HPR decreased the expression Bcl-xL in a timedependent manner. These results suggest that the altered Bcl-xL expression may be responsible for 4HPR-induced cytochrome c release and mitochondrial damage, but that the activation of Bid or the induction of proapoptotic Bax may not be involved in 4HPR-induced cytochrome c release and mitochondrial damage in Fas-defective hepatoma cells.
DISCUSSION
Chemotherapeutic drugs, such as doxorubicin, methotrexate, or bleomycin, induce the up-regulation of membrane Fas and Fas-L expression, which is followed by the induction of Fas-dependent apoptosis. [14] [15] [16] Alternatively, antitumor drugs may induce apoptosis by another pathway. 18, 32, 33 In this study, we observed that 4HPR triggered apoptosis in Fas-pos- itive and in Fas-negative hepatoma cells, although Fas-negative hepatoma cells were more susceptible to apoptosis than were Fas-positive cells. Considering that Hep 3B and PLC/ PRF/5 cells had impaired p53 function while Hep G2 and SK-HEP-1 express wild-type p53, 34 4HPR-induced apoptosis must be independent of p53 function, as described previously. 35, 36 Although FADD functions primarily as a death-receptor adaptor molecule essential for the recruitment and activation of caspase-8, 21,37 it does not play a role in apoptosis induced by certain chemotherapeutic agents such as adriamycin. 37 In contrast, other agents such as cycloheximide mediate cell death in certain cells through a FADD-dependent mechanism that does not involve the action of the cell-surface Fas death receptor. 39 In this study, we have shown that 4HPR-induced apoptosis is also independent of FADD function in Fas-defective hepatoma cells. However, 4HPR-induced apoptosis was significantly inhibited by E1B19K, by pox virus serpin CrmA, and by dnFLICE, which are direct inhibitors of caspase-8, implying that this drug-induced apoptosis is dependent on caspase-8 activation.
In addition to apoptosis assays in cells stably expressing E1B 19K, Crm A, or dnFLICE, studies using specific inhibitors show that the direct activation of caspase plays a critical role in cell-death execution. The 4HPR-induced apoptosis could be almost completely inhibited by the addition of a general caspase inhibitor, Z-VAD-FMK, or a caspase-8 inhibitor, IETD-CHO, but was only partially inhibited by antioxidants or by a calpain inhibitor I. Thus, oxidative stress and calpain activation are also involved in this cell-death process. Recently, the caspase-dependent activation of calpain was reported to occur during drug-induced apoptosis. 40 Generation of H 2 O 2 that is commonly detected after treatment with drugs and scavenging of H 2 O 2 prevented cells from undergoing apoptosis, 41 implying that oxidative stress is involved in anticancer drug-induced apoptosis. Similarly, 4HPR stimulates the generation of intracellular free radicals, which appear to have a causative role in the induction of apoptosis in vitro. 8, 9, 42 The capase-3 inhibitor did not completely inhibit 4HPR-induced apoptosis, and thus an alternative pathway seems to work in this drug-induced apoptosis. In this study, the time-sequence analysis of the induction of apoptosis by 4HPR revealed that activation of caspase-8 occurred after 24 hours of exposure, relevant cell death had occurred after 48 hours, and cytochrome c was released after 72 hours. Thus, the time course of caspase activation and apoptosis is surprisingly long with respect to rapid receptormediated caspase activation. 43 This delay of cell death may result from non-receptor-mediated activation of caspase-8 by 4HPR. However, its underlying mechanism should be further elucidated. The release of cytochrome c was a late event, and may have occurred as a result of cell death or from the mitochondrially localized apoptosis-inducing factor, which is released in response to death stimuli and which acts upstream of cytochrome c release. 44 Caspase-9 activation was much less than caspase-8 activation in the caspase activity assay and in the inhibition assay, but it was not detected by Western blot analysis.
We next examined the possibility of whether the caspase-9 activation observed in 4HPR-induced apoptosis was mediated by activated Bid through caspase-8 activation, because the activated Bid (p15 tBid, generated from the cleavage of inactive p22 cytosolic Bid) is capable of targeting mitochondria, where it triggers cytochrome c release, 26, 45 particularly during Fas or tumor necrosis factor-induced apoptosis. 29, 30 However, the role of Bid is unclear in non-receptor-mediated forms of apoptosis. Considering that antioxidants (including NAC, PDTC, and NGDA) can partially inhibit cell death, 4HPR may induce cell death primarily by caspase-8 activation, and may subsequently induce cytochrome c release and caspase-9 activation that results in oxidative stress during the late stage. This late pathway of cell death does not seem to be associated with Bid activation in Fas-defective Hep 3B cells. Thus Bid, which is essential in Fas-induced cell death of hepatocytes, 30 does not seem to be involved in this type of nonreceptor-mediated apoptosis in the Fas-defective cells. 4HPR may activate caspase-8 and trigger apoptosis through activation of downstream caspases with no involvement of mitochondria as the endoplasmic reticulum stress induces apoptosis through caspase-12 activation. 46 Furthermore, nuclear orphan receptor TR3 in response to the synthetic retinoid, 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid, translocates from the nucleus to mitochondria to induce cytochrome c release and apoptosis. 47 These pathways may be responsible for the absence of Bid activation, although the exact underlying mechanism(s) is unclear. Bax is a proapoptotic member of the Bcl-2 family and has been shown to induce cytochrome c release. [48] [49] [50] [51] Bax is normally localized in the cytosol and can be actively translocated to mitochondria during apoptosis. It serves at the end of the common apoptosis signal transduction pathway to induce cytochrome c release. We demonstrated in this study that Bax is not involved in 4HPR-induced mitochondrial damage in Hep 3B cells that do not have a functional p53 gene. Bax is one of the target genes downstream of p53-induced apoptosis. 52 Additionally, apoptotic suppressors have functions downstream of cytochrome c release. [53] [54] [55] Bcl-2 and Bcl-xL proteins block the effects of Bax, Bad, or other apoptosis effectors on mitochondria and consequently block cytochrome c release. Decreased Bcl-xL expression by 4HPR was observed in Hep 3B cells. Thus, we assume that 4HPR induces mitochondrial damage through an alternative pathway to the activation of Bid mediated by activated caspase-8 and to the expression of proapoptotic Bax. The altered Bcl-xL expression may be involved in the late cytochrome c release. 4HPR can damage mitochondria by interruption of the respiratory chain complex. 56 In addition, the attenuated caspase-9 activation by 4HPR, despite the overt cytochrome c release at the late period of apoptosis, suggests that a certain inhibitory factor(s) of apoptosis, such as inhibitors of apoptosis, may exist in cells. 57, 58 Nuclear factor-B (NF-B), which is known to be a transcriptional regulator of antiapoptotic gene expression, confers chemoresistance to cancer cells. 59, 61 Thus, we checked NF-B activation during 4HPR-induced apoptosis to examine whether the balance of pro-and antiapoptotic signals toward cell death is changed. NF-B was activated and treatment with an inhibitor of NF-B enhanced 4HPR sensitivity (data not shown). Furthermore, inhibition of transcription by actinomycin D enhanced 4HPR-induced apoptosis, but inhibition of protein synthesis by cycloheximide had no effect (data not shown). Thus, NF-B activation and NF-B-dependent transcription may play a role in tumor-cell survival in this system. This study provides evidence that caspase-8 activation plays a major role in 4HPR-triggered apoptosis. However, 4HPR/caspase-8 interactions should be more carefully investigated to rule out the possible involvement of caspase-10 and to conclusively demonstrate that caspase-8 -negative cells 59 are resistant to 4HPR-induced apoptosis.
Desirable chemotherapeutic drugs should be capable of effectively inducing apoptosis in cancer cells, and this induction should be independent of p53/Fas function because many tumors have defects of these functions. Thus, in terms of p53/ Fas-independent caspase activation, 4HPR may be useful for treating hepatoma or other tumors as an effective anticancer drug.
